IDiyas

For the Inventor, By the Inventor

Rahway, NJ, United States of America

Edward S Inamine

USPTO Granted Patents = 17

Average Co-Inventor Count = 3.7

ph-index = 5

Forward Citations = 95(Granted Patents)


Company Filing History:

goldMedal17 out of 4,770 
 
Merck + Co., Inc.
 patents

Years Active: 1976-1994

Loading Chart...
17 patents (USPTO):Explore Patents
1. 5290772 - Immunosuppressant agent (1994-03-01),
2. 5268370 - Microbial transformation product of L-679,934 (1993-12-07),
3. 5252612 - Microbial immunosoppressant agent (1993-10-12),
4. 5250422 - Biotransformation process for the production of invermectin derivatives (1993-10-05),
5. 5202258 - Immunosuppressant-producing culture (1993-04-13),
6. 5116870 - HMG-CoA reductase inhibitors (1992-05-26),
7. 5087702 - Microbial transformation process for producing an antihypertensive (1992-02-11),
8. 5070015 - Novel avermectins are produced from known microorganisms (1991-12-03),
9. 4997755 - HMG-CoA reductase inhibitors produced by Nocardia sp. (MA 6455) (1991-03-05),
10. 4981792 - Immunosuppressant compound (1991-01-01),
11. 4975372 - Microbial transformation product of L-683,590 (1990-12-04),
12. 4940727 - Novel HMG-CoA reductase inhibitors (1990-07-10),
13. 4766112 - Anthelmintic fermentation products of a microorganism (1988-08-23),
14. 4696925 - Cholecystokinin antagonist compounds (1987-09-29),
15. 4668696 - Novel averonectin fermentation product of a microorganism with (1987-05-26),

Title: The Innovative Legacy of Edward S. Inamine

Introduction

Edward S. Inamine, a prolific inventor based in Rahway, NJ, has left an indelible mark on the field of immunosuppressant agents through his groundbreaking work. With a remarkable 17 patents to his name, Inamine's contributions have significantly advanced the treatment of organ transplant rejection.

Latest Patents

Among his latest patents, Inamine has introduced the immunosuppressant agent 'demethimmunomycin' (L-683,7411) and the microbial transformation product of L-679,934, known as L-683,519. These innovations have paved the way for more effective prevention of human host rejection in organ transplants such as bone marrow and heart transplants. The use of microorganisms like Actinoplanacete sp and Actinomycete in the production process showcases Inamine's adeptness in harnessing biotechnological solutions for medical advancements.

Career Highlights

Edward S. Inamine is a key figure at Merck & Company, Inc., where he has honed his expertise in pharmaceutical research and development. His tenure at Merck has been marked by a series of groundbreaking discoveries that have reshaped the landscape of immunosuppressant therapies. Inamine's commitment to innovation and scientific rigor has solidified his reputation as a leading authority in the field.

Collaborations

In his collaborative efforts, Inamine has worked closely with esteemed colleagues such as Shieh-Shung T Chen and Byron H. Arison. The synergy between these brilliant minds has resulted in synergistic projects that have pushed the boundaries of medical science and improved patient outcomes. Through effective teamwork and mutual respect, Inamine and his coworkers have established a legacy of excellence in pharmaceutical research.

Conclusion

Edward S. Inamine stands as a testament to the power of innovation and perseverance in the realm of medical research. His pioneering work in the development of immunosuppressants has opened up new possibilities for organ transplant recipients worldwide. With a keen eye for scientific discovery and a relentless drive for excellence, Inamine continues to inspire future generations of inventors and researchers in the quest for medical advancements.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…